Pharmaceutical Companies Push Trump Administration to Protect China Deals

A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。